Skip to main content

Table 2 The pharmacological effect of QBD in clinical trials

From: Potential therapeutic effect of Qingwen Baidu Decoction against Corona Virus Disease 2019: a mini review

Disease

Gender (M/F)

Age (years) (range, mean)

Interventions

Course

Clinical efficiency

Reported indicators in QBD group

References

Sepsis

E: 11/7

C: 12/8

E: 53.27 ± 9.24

C: 51.00 ± 11.29

E: Conventional therapy + QBD (100 ml/time, tid.)

C: Conventional therapy

7 days

E: 83.33%

C:75.00%

IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓, APACHEII score↓, TCM symptom score↓

Zhang et al. [51]

Sepsis

E: 18

C: 20

NR

E: Conventional therapy + QBD (100 ml/time, tid.)

C: Conventional therapy

7 days

E: 83.33%

C: 75.00%

TCM symptom score↓, APACHEII score↓, IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓

Leng et al. [18]

Sepsis

E: 11/7

C: 12/8

E: 53.27 ± 9.24

C: 51.00 ± 11.29

E: Conventional therapy + QBD (200 ml/time, tid.)

C: Conventional therapy

7 days

E: 83.30%

C: 75.00%

TCM symptom score↓, APACHEII score↓, mortality rate↓, PT↓, APTT↓, TT↓, PLT↑

Fu et al. [54]

Sepsis

E: 15/10

C: 16/8

E: 53.27 ± 9.20

C: 51.00 ± 11.29

E: Conventional therapy + QBD (100 ml/time, tid.)

C: Conventional therapy

7 days

E: 84.00%

C: 75.00%

TCM symptom score↓, APACHEII score↓, IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓

Leng et al. [52]

Sepsis

E: 19/23

C: 22/20

E: 50–74, 61 ± 8.6

C: 52–75, 63 ± 7.3

E: Antibiotic therapy + QBD (100 ml/time, bid.)

C: Antibiotic therapy

7 days

E: 80.95%

C: 64.28%

APACHEII score↓, IgG, ↓ IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓

Chen [17]

AKI with sepsis

E: 28/29

C: 30/26

E: 68.10 ± 9.07

C: 69.49 ± 8.37

E: Conventional therapy + QBD (200 ml/day, bid.)

C: Conventional therapy

7 days

NR

APACHEII score↓, Scr↓, BUN↓, CRP↓, TNF-α↓, IL-1β↓, IL-6↓, IL-10↓

Ge et al. 2014 [37]

Pathogen-invading-lung syndrome with sepsis

E: 15/9

C: 13/11

E: 68.10 ± 9.07

C: 69.49 ± 8.37

E: Conventional therapy + QBD (100 ml/time, bid.)

C: Conventional therapy

7 days

E: 95.83%

C: 83.33%

APACHEII score↓, CRP↓, WBC↓, TCM symptom score↓, blood glucose↑, antipyretic time↓

Xi et al. [20]

Sepsis with heat poisoning syndrome

E: 35/24

C: 37/21

E: 46–68, 50.4 ± 8.5

C: 44–70, 51.8 ± 7.9

E: Conventional therapy + Xuebijing injection (100 mg/time, bid.) + QBD (200 mg/time, bid.)

C: Conventional therapy

7 days

E: 77.97%

C: 42.37%

APACHEII↓, SOFA score↓, TNF-α↓, IL-1β↓, IL-6↓, IL-10↑, d-lactic acid↓, endotoxin↓, PCT↓, whole blood viscosity↓, plasma viscosity↓, erythrocyte deformation index↓, erythrocyte aggregation index↓, PT↑, APTT↓, TT↑, FIB↓, D–D↓, PLT↓

Ren et al. [14]

Coagulation dysfunction in sepsis

E: 20/13

C: 19/12

E: 28–78, 60.94 ± 12.13

C: 28–79, 61.45 ± 12.91

E: Conventional therapy + QBD (100 ml/day, bid.)

C: Conventional therapy

7 days

E: 93.90%

C: 74.20%

PLT↑, PT↓, APTT↓, Fib↓, D–D↓, TCM symptom score↓, APACHEII score↓, SOFA score↓

Gao et al. [19]

Influenza A (H1N1) with respiratory distress syndrome

2/11

12–61, 29.4 ± 14.1

Conventional therapy + QBD

7–48 days

92.31%

11 cases were cured, 1 case was effective and 1 case was ineffective

Chu et al. [40]

Viral pneumonia caused by influenza A virus subtype H1N1

E: 28/22

C: 24/16

E: 40.67 ± 2.09

C: 41.68 ± 4.68

E: Conventional therapy + QBD (200 ml/day, tid.) + Tanreqing injection (30 ml/day, qd.)

C: Conventional therapy

7 days

E: 96.00%

C: 70.00%

TNF-α↓, IL-6↓, IL-8↓, IL-10↑, CRP↓, TCM symptom score↓

Tian et al. [15]

SARS

4/6

15–70, 43.77 ± 12.68

Conventional therapy + QBD (150 ml/time, bid.)

5 days

NR

Antipyretic time↓, temperature gradually drops to normal level

Zhang et al. [45]

EV 71

E: 22/8

C: 21/9

E: 2.0 ± 1.3

C: 2.1 ± 0.25

E: Conventional therapy + QBD (50 ml/time, bid. ~ tid.)

C: Conventional therapy

3–5 days

E: 93.33%

C: 63.40%

Antipyretic time↓, hospital stay↓

Zhan et al. [43]

Epidemic encephalitis type B

10/6

1–11, 5.3

QBD (tid.)

NR

87.50%

10 cases were cured, 4 cases were improved and 2 cases were ineffective.

Yang [33]

Pneumonia

E: 30

C: 30

(36/24)

E: 20–70, 53.11 ± 10.58

C: 18–67, 49.00 ± 10.61

E: Levofloxacin + QBD (150 ml/time, bid.)

C: Levofloxacin (0.5 g, qd.)

7 days

E: 96.67%

C: 86.67%

Antipyretic time↓, WBC↓, NG↓

Nie et al. [66]

Mycoplasma pneumonia

E: 20/25

C: 22/23

E: 9–58, 27

C: 10–63, 25

E: Azithromycin (10 mg/kg/day, i.v.) + QBD + Canopy bulk

C: Azithromycin (10 mg/kg/day, i.v.)

4 W

E: 100.00%

C: 86.67%

Blood routine was normal, clinical symptoms disappeared, chest X-ray improved

Shu [67]

Infant pneumonia

E: 22/20

C: 23/20

E: 0.58–9

C: 0.58–8

E: Conventional therapy + QBD (3–5 ml/kg, bid.)

C: Conventional therapy

5 days

E: 97.62%

C: 81.40%

NR

Yao et al. [30]

Epidemic hemorrhagic fever

E: 84/36

C: 40/20

E: 10–17 (13 cases); 18–49 (82 cases), 50–70 (25 cases)

C: 10–17 (4 cases); 18–49 (47 cases), 50–70 (9 cases)

E: Ribavirin (15 mg/kg, qd.) + QBD (bid.)

C: Ribavirin (15 mg/kg, qd.)

NR

NR

Days of fever↓, polyuria↓, platelet recovery↓, urine protein turning negative↓, the rate of oliguria and hypotension shock↑, adverse reactions ↓

Hao et al. [27]

Hyperthermia

E: 14/12

C: 11/15

E: 18–62

C: 19–63

E: QBD (150 ml/time, bid.)

C: Angong Niuhuang Pill (1 pill, qd ~ bid.)

NR

E: 92.30%

C: 57.69%

NR

Wang et al. [55]

Hemorrhagic fever with renal syndrome

E: 45

C: 45

(51/39)

24–48

E: Conventional therapy + QBD (bid.)

C: Conventional therapy

7 days

NR

CD4+↑, CD8+↓,

CD4+/CD8+↑

Li et al. [26]

Infectious mononucleosis

E: 46

C: 45

(43/48)

0.83–6

E: Ganciclovir (10 mg/kg d, bid.) + QBD (bid. ~ tid.)

C: Ganciclovir (10 mg/kg d, bid.)

7 days

E: 93.48%

C: 80.00%

NR

Dong [41]

Infectious mononucleosis in children

E: 11/9

C: 12/8

E: 2–13

C: 3–12

E: ganciclovir (5 mg/kg) + QBD (200 ml/time, qid.)

C: ganciclovir (5 mg/kg)

7–14 days

E: 95.00%

C: 80.00%

Duration of main clinical manifestations↓, WBC↓, heterotypic lymphocyte↓, liver function indices↓

Sheng et al. [42]

Epidemic cerebrospinal meningitis

40/22

8–40, 18

QBD (tid.)

15 days

98.39%

NR

Sun et al. [29]

Hand-foot-and-mouth disease

E: 30/20

C: 25/25

E: 1–3 (37 cases), 4–5 (13 cases)

C: 1–3 (36 cases), 4–5 (14 cases)

E: Ribavirin (10–15 ml/kg, qd.) + QBD (100–150 ml/day, tid. ~ qid.)

C: Ribavirin (10–15 ml/kg, qd.)

10 days

E: 94.00%

C: 88.00%

Antipyretic time↓, disappearance time of oral herpes↓, severe conversion rate↓

Xu et al. [68]

Erythroderma psoriasis

E: 14/15

C: 16/13

E: 20–63, 46.35 ± 2.16

C: 20–64, 47.32 ± 2.61

E: QBD (200 ml/time, tid.)

C: Acitretin capsules (20 mg/kg)

3 M

E: 96.55%

C: 75.86%

Adverse reactions ↓

Li [69]

  1. E experimental group, C control group, W week, APACHE acute physiology and chronic health evaluation, M month(s), WBC white blood cell, EV enterovirus, SOFA sequential organ failure assessment, NG neutrophil granulocyte, CRP C-reactive protein, PLT platelet count, PT prothrombin time, APTT activated partial thromboplastin time, TT thrombin time, Fib fibrinogen, D-D D-Dimer, AKI acute kidney injury, BUN blood urea nitrogen, NR not report